Resource Type

Journal Article 163

Conference Videos 4

Year

2023 14

2022 16

2021 16

2020 11

2019 17

2018 7

2017 9

2016 9

2015 7

2014 10

2013 3

2012 11

2011 3

2010 5

2009 12

2008 4

2007 3

2006 1

2000 1

1999 2

open ︾

Keywords

targeted therapy 8

cancer therapy 7

therapy 6

SARS-CoV-2 5

cancer 5

gene therapy 5

immunotherapy 5

COVID-19 4

monoclonal antibody 4

Antibody response 2

Coronavirus disease 2019 2

Efficacy 2

antibody 2

boron neutron capture therapy 2

cancer immunotherapy 2

clinical trial 2

drug resistance 2

hepatocellular carcinoma 2

polyclonal antibody 2

open ︾

Search scope:

排序： Display mode:

Passive antibody therapy in emerging infectious diseases

Frontiers of Medicine doi: 10.1007/s11684-023-1021-y

Abstract: Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonalIn addition, the prospects of applying antibody therapy against VOCs was assessed, offering insights

Keywords： SARS-CoV-2     COVID-19     convalescent plasma     hyperimmunoglobulin     neutralizing monoclonal antibodies    

HTML PDF Collect

CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells

Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao

Frontiers of Medicine 2016, Volume 10, Issue 2,   Pages 204-211 doi: 10.1007/s11684-016-0443-1

Abstract: A positive clone of CD176 single-chain variable antibody fragment (scFv) was successfully screened from

Keywords： CD176     Thomsen-Friedenreich antigen     scFv     cancer     therapy     adhesion     metastasis    

HTML PDF Collect

Antibody Therapies Targeting Complex Membrane Proteins Review

Georgina To´a Salazar, Ziyi Huang, Ningyan Zhang, Xue-Guang Zhang, Zhiqiang An,

Engineering 2021, Volume 7, Issue 11,   Pages 1541-1551 doi: 10.1016/j.eng.2020.11.013

Abstract: conformations of a particular membrane protein, as well as adaptability through engineering into various antibodyion channels, transporters, and membrane-bound enzymes can be addressed by the design of the antigen, antibody-generationstrategies, lead optimization technologies, and antibody modalities.complex membrane proteins with antibodies and discusses the preparation of membrane protein antigens and antibody

Keywords： Antibody therapy     Complex membrane protein     Ion channels     Transporters     Membrane-bound enzymes     GPCRs    

HTML PDF Collect

Current State of Monoclonal Antibody Therapy for Allergic Diseases Review

Yan Chen, Wei Wang, Huihui Yuan, Yan Li, Zhe Lv, Ye Cui, Jie Liu, Sun Ying

Engineering 2021, Volume 7, Issue 11,   Pages 1552-1556 doi: 10.1016/j.eng.2020.06.029

Abstract:

Allergic disease is one of the most common chronic diseases, which can affect both children and adults, be often caused by allergen-induced unfavorable immune responses, and initiate various symptoms in different organs, including up-/low-airways and skin, such as asthma, atopic dermatitis, and rhinosinusitis. With increasing prevalence of allergic disease worldwide and their impact on the quality of life, new biological therapeutic approaches for these disorders become hot areas of intensive research. Multiple factors are involved and play important role in the pathogenesis of allergic disease, which can promote or trigger T helper 2 (Th2)-type immune responses, leading to production of the type 2 cytokines and immunoglobulin E (IgE)，the two critical events in the allergic diseases. Using monoclonal antibodies to target these molecules, therefore, might provide possible benefits for the patients suffered from these diseases. Apart of those having approved biologics for allergic diseases, some potential targets such as epithelial-derived alarmins thymic stromal lymphopoietin (TSLP) and interleukin 33 (IL-33) have been also described and proposed to develop monoclonal antibodies against either these cytokines, their receptors, or both. These new and potential targets have substantially enriched the therapeutic opportunities in the field of allergic diseases. The present review aims to briefly outline the role of monoclonal antibodies targeting the cytokines and immunoglobulin involved in the development of allergic diseases, and to discuss the clinical effects of these antibodies.

Keywords： Allergic disease     Monoclonal antibody     Anti-IgE     Cytokines     Clinical trials    

HTML PDF Collect

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Frontiers of Medicine doi: 10.1007/s11684-023-0996-8

Abstract: Here, we discovered that BGB-A445, a non-ligand-competitive agonistic anti-OX40 antibody currently underdose-dependently and significantly depleted regulatory T cells in vitro and in vivo via antibody-dependentdemonstrated robust and dose-dependent antitumor efficacy, whereas the ligand-competitive anti-OX40 antibodyFurthermore, BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody.

Keywords： BGB-A445     OX40     agonistic antibody     OX40L noncompetitive    

HTML PDF Collect

How to judge the association of postmenopausal hormone therapy and the risk of breast cancer

Ling XU

Frontiers of Medicine 2010, Volume 4, Issue 3,   Pages 290-293 doi: 10.1007/s11684-010-0093-7

Abstract: The relevance of postmenopausal hormone therapy (HT) for breast cancer risk has been long debated, althoughThese unanswered questions include: whether HT has a positive impact on breast cancer; whether risks of therapy

Keywords： breast cancer     postmenopausal hormone therapy     unopposed estrogen therapy     combined estrogen-progestin therapy    

HTML PDF Collect

Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv

Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT

Frontiers of Chemical Science and Engineering 2012, Volume 6, Issue 2,   Pages 216-223 doi: 10.1007/s11705-012-1289-y

Abstract: The objective of this work was to produce a polyclonal antibody against VP26 and use it as a biosensorprotein (rVP26) was produced in (BL21), purified and used for immunizing rabbits to obtain a polyclonal antibody

Keywords： recombinant protein     polyclonal antibody     label-free biosensor     impedance     white spot syndrome virus (WSSV    

HTML PDF Collect

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 83-93 doi: 10.1007/s11684-019-0682-z

Abstract: Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC haveand S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibodyFurthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependent

Keywords： S492R EGFR ectodomain mutation     colorectal cancer     mAb CH12     immunnotherapy    

HTML PDF Collect

Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples

Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA

Frontiers of Environmental Science & Engineering 2011, Volume 5, Issue 3,   Pages 409-416 doi: 10.1007/s11783-011-0349-8

Abstract: The monoclonal antibody with high level of binding affinity for Cd-IEDTA-BSA and high specificity for

Keywords： cadmium     hapten     monoclonal antibody     enzyme-linked immunosorbent assay (ELISA)    

HTML PDF Collect

Particle therapy for cancers: a new weapon in radiation therapy

Guo-Liang Jiang

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 165-172 doi: 10.1007/s11684-012-0196-4

Abstract: and intensity-modulated radiation therapy, proton therapy has yielded more promising outcomes in localCarbon therapy in Japan showed even more promising results than proton therapy.The non-invasive nature of particle therapy affords more patients with chances to receive and benefitParticle therapy is gradually getting attention from the oncology community.However, the cost of particle therapy facilities has limited the worldwide use of this technology.

Keywords： radiation therapy     particle therapy     proton     carbon     cancer    

HTML PDF Collect

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Frontiers of Medicine 2021, Volume 15, Issue 2,   Pages 221-231 doi: 10.1007/s11684-020-0812-7

Abstract: rationale, the intriguing question is why cancers are insensitive or not responsive to mTOR-targeted cancer therapyERK, and Mnk/eIF4E survival signaling pathways that compromise the efficacy of rapalog-based cancer therapyThese new findings may also offer us the opportunity to rationally utilize mTOR inhibitors in cancer therapy

Keywords： mTOR     cancer therapy     resistance     GSK3     protein degradation     E3 ubiquitin ligase     PD-L1    

HTML PDF Collect

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Frontiers of Medicine 2019, Volume 13, Issue 4,   Pages 427-437 doi: 10.1007/s11684-018-0672-6

Abstract: Tyrosine kinase and γ-secretase inhibitors are primarily used in the targeted therapy of DF.Previous studies that focused on the mechanism, efficacy, and safety of targeted therapy for DF wereThe efficacy and safety of targeted therapy were compared with those of other systemic therapy optionsTargeted therapy does not provide considerable advantages in efficacy and safety over other medical treatmentsstudies are required to explore the mechanism, indications, and appropriate drug dosage of the targeted therapy

Keywords： targeted therapy     desmoid-type fibromatosis     tyrosine kinase inhibitor     γ-secretase inhibitor    

HTML PDF Collect

Modified Therapeutic Antibodies: Improving Efficacy Review

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Engineering 2021, Volume 7, Issue 11,   Pages 1529-1540 doi: 10.1016/j.eng.2020.06.030

Abstract: of crystallizable domain (Fc) amino acid alterations; ③ cross-isotype or cross-subclass exchanges; ④ antibody

Keywords： Therapeutic antibody     Modification     Efficacy     Antigen     Antibody–drug conjugate     Bispecific antibody    

HTML PDF Collect

Hydroxyl radical-involved cancer therapy via Fenton reactions

Frontiers of Chemical Science and Engineering 2022, Volume 16, Issue 3,   Pages 345-363 doi: 10.1007/s11705-021-2077-3

Abstract: Furthermore, the challenges and future developments of hydroxyl radical-involved cancer therapy are discussed

Keywords： hydroxyl radical     Fenton catalyst     hydrogen peroxide     cancer therapy    

HTML PDF Collect

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 1-10 doi: 10.1007/s11684-020-0741-5

Abstract: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a heterogeneous genetic profile. Chemotherapy exhibits substantial activity in a small subset of these patients. Drug resistance is inevitable. Major progress has been made in the genetic analysis of TNBC to identify novel targets and increase the precision of therapeutic intervention. Such progress has translated into major advances in treatment strategies, including modified chemotherapy approaches, immune checkpoint inhibitors, and targeted therapeutic drugs. All of these strategies have been evaluated in clinical trials. Nevertheless, patient selection remains a considerable challenge in clinical practice.

Keywords： triple-negative breast cancer     immunotherapy     targeted therapy    

HTML PDF Collect

Title Author Date Type Operation

Passive antibody therapy in emerging infectious diseases

Journal Article

CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells

Jiangnan Liu,Bin Yi,Zhe Zhang,Yi Cao

Journal Article

Antibody Therapies Targeting Complex Membrane Proteins

Georgina To´a Salazar, Ziyi Huang, Ningyan Zhang, Xue-Guang Zhang, Zhiqiang An,

Journal Article

Current State of Monoclonal Antibody Therapy for Allergic Diseases

Yan Chen, Wei Wang, Huihui Yuan, Yan Li, Zhe Lv, Ye Cui, Jie Liu, Sun Ying

Journal Article

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Journal Article

How to judge the association of postmenopausal hormone therapy and the risk of breast cancer

Ling XU

Journal Article

Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv

Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT

Journal Article

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Journal Article

Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples

Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA

Journal Article

Particle therapy for cancers: a new weapon in radiation therapy

Guo-Liang Jiang

Journal Article

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Journal Article

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Journal Article

Modified Therapeutic Antibodies: Improving Efficacy

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Journal Article

Hydroxyl radical-involved cancer therapy via Fenton reactions

Journal Article

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Journal Article